Drug Profile
Imaradenant - AstraZeneca/Nxera Pharma
Alternative Names: AZD 4635; HLT 1071; HTL-1071Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Heptares Therapeutics
- Developer Nxera Pharma
- Class Amines; Antineoplastics; Chlorinated hydrocarbons; Fluorobenzenes; Pyridines; Small molecules; Triazines
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Prostate cancer
- No development reported Cancer; Solid tumours
Most Recent Events
- 31 Mar 2024 Sosei Heptares is now called Nxera Pharma
- 11 Apr 2023 AstraZeneca completes a phase II trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in USA (PO) (NCT04089553)
- 31 Mar 2023 AstraZeneca completes a phase I trial in Cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02740985)